Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 137 matching trials from the live ClinicalTrials.gov search.
Conditions
Stroke, Stroke, Acute, Balance; Distorted, Balance; Impairment, Gait, Unsteady
Interventions
Body weight support system control group, Body weight support system with balance perturbations
Device
Lead sponsor
Gaylord Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Wallingford, Connecticut • Washington D.C., District of Columbia • Sandwich, Massachusetts + 1 more
Conditions
Hepatitis C
Interventions
Data-assisted Case Navigation, Standard of Care
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Psychotic Disorders
Interventions
Electronic Screen + Education (Phase 1), Targeted Provider Education (Phase 1), Community Mobile Engagement (Phase 2), Clinic based Engagement (Phase 2)
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
Burn Injury
Interventions
Tacrolimus ointment
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetic Foot Ulcer
Interventions
SOC and Advanced Bioengineered Skin Substitute, SOC and Active Comparator
Device · Other
Lead sponsor
Encoll Corp
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • South Miami, Florida • Salem, Virginia
Conditions
Food Allergy in Children, Food Allergy
Interventions
use of virtual reality, use of standard technology
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Conditions
Schizophrenia
Interventions
ANAVEX3-71 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Anavex Life Sciences Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Marlton, New Jersey
Conditions
Stroke, Stroke Sequelae, Hemiparesis;Poststroke/CVA
Interventions
StrokeWear Behavioral Intervention, Usual Care + Sham
Behavioral · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Loneliness, Opioid Use Disorder
Interventions
Marigold Mobile Peer Support Intervention, Resources
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
HIV, Heart Failure
Interventions
Exercise Intervention, Tailored Education sessions, Behavioral coaching, Mobile health support, General education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Conditions
Infant, Premature, Neonatal Respiratory Distress, Oxygen Saturation, Bronchopulmonary Dysplasia
Interventions
Automated Control, Manual Control
Device
Lead sponsor
Vapotherm, Inc.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Salt Lake City, Utah • Seattle, Washington
Completed Not applicable Interventional Results available

Donors After Circulatory Death Heart Trial

NCT03831048
Conditions
Heart Transplant
Interventions
OCS Heart System, Cold Storage
Device · Other
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Pharmacist review of therapy
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Trenton, New Jersey
Completed Phase 2 Interventional Results available

Oral Rivaroxaban in Children With Venous Thrombosis

NCT01684423
Conditions
Venous Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more
Conditions
Total Knee Arthroplasty, Rehabilitation
Interventions
Anti-gravity treadmill, PENS - neuro-muscular stimulation, Anti-gravity treadmill & PENS - neuro-muscular stimulation, Recumbent or Nu-step bike
Other
Lead sponsor
MedStar National Rehabilitation Network
Other
Eligibility
40 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Hemiparesis
Interventions
Myomo Robotic Arm, RTP Standard Therapy
Device · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
35 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Perinatal Depression
Interventions
Longitudinal Remote Consultation, Collaborative Care
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Postoperative Pain, Recovery
Interventions
Intravenous Methadone, Short-acting Opioids Intraoperative analgesia
Drug
Lead sponsor
Alexandre P. Joosten
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Irvine, California
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized Xenon-129 MRI (Experimental), Radioactive Xenon-133 scintigraphy (Active Comparator)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Conditions
Hemodialysis
Interventions
Novel Physical Activity Program, Standard of Care Physical Activity Program
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Bolingbrook, Illinois • Oak Brook, Illinois • Urbana, Illinois
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more